Accent Therapeutics and AstraZeneca (NYSE:AZN) will collaborate
to discover, develop and commercialize transformative therapeutics
targeting RNA-modifying proteins for the treatment of cancer.
Under the terms of agreement, Accent will be
responsible for research, development and commercialization activities
for a nominated preclinical program through to the end of Phase I
clinical trials, with the company having the option to jointly develop
and commercialize in the US.
Accent will receive an upfront payment of $55M
and is eligible for up to ~$1.1B in total additional milestones, plus
tiered royalties, under co-development and co-commercialization
arrangement.
AstraZeneca will also have the exclusive option to license worldwide rights to two further preclinical discovery programs.
https://seekingalpha.com/news/3580309-astrazeneca-inks-deal-accent-therapeutics-to-develop-novel-cancer-therapeutics
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.